Browse MDH1B

Summary
SymbolMDH1B
Namemalate dehydrogenase 1B, NAD (soluble)
Aliases FLJ25341; RP11-95H11; Putative malate dehydrogenase 1B
Chromosomal Location2q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain -
Function

-

> Gene Ontology
 
Biological Process GO:0006091 generation of precursor metabolites and energy
GO:0006099 tricarboxylic acid cycle
GO:0006107 oxaloacetate metabolic process
GO:0006108 malate metabolic process
GO:0006732 coenzyme metabolic process
GO:0006733 oxidoreduction coenzyme metabolic process
GO:0006734 NADH metabolic process
GO:0009060 aerobic respiration
GO:0015980 energy derivation by oxidation of organic compounds
GO:0019362 pyridine nucleotide metabolic process
GO:0019674 NAD metabolic process
GO:0043648 dicarboxylic acid metabolic process
GO:0045333 cellular respiration
GO:0046496 nicotinamide nucleotide metabolic process
GO:0051186 cofactor metabolic process
GO:0072524 pyridine-containing compound metabolic process
Molecular Function GO:0016614 oxidoreductase activity, acting on CH-OH group of donors
GO:0016615 malate dehydrogenase activity
GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0030060 L-malate dehydrogenase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMDH1B
Namemalate dehydrogenase 1B, NAD (soluble)
Aliases FLJ25341; RP11-95H11; Putative malate dehydrogenase 1B
Chromosomal Location2q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MDH1B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMDH1B
Namemalate dehydrogenase 1B, NAD (soluble)
Aliases FLJ25341; RP11-95H11; Putative malate dehydrogenase 1B
Chromosomal Location2q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MDH1B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMDH1B
Namemalate dehydrogenase 1B, NAD (soluble)
Aliases FLJ25341; RP11-95H11; Putative malate dehydrogenase 1B
Chromosomal Location2q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MDH1B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1430.564
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2350.611
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4140.259
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1560.73
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5050.639
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.290.807
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3680.441
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2040.77
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7850.341
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.8720.251
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.2240.216
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0960.625
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MDH1B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMDH1B
Namemalate dehydrogenase 1B, NAD (soluble)
Aliases FLJ25341; RP11-95H11; Putative malate dehydrogenase 1B
Chromosomal Location2q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MDH1B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMDH1B
Namemalate dehydrogenase 1B, NAD (soluble)
Aliases FLJ25341; RP11-95H11; Putative malate dehydrogenase 1B
Chromosomal Location2q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MDH1B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MDH1B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMDH1B
Namemalate dehydrogenase 1B, NAD (soluble)
Aliases FLJ25341; RP11-95H11; Putative malate dehydrogenase 1B
Chromosomal Location2q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MDH1B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMDH1B
Namemalate dehydrogenase 1B, NAD (soluble)
Aliases FLJ25341; RP11-95H11; Putative malate dehydrogenase 1B
Chromosomal Location2q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MDH1B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMDH1B
Namemalate dehydrogenase 1B, NAD (soluble)
Aliases FLJ25341; RP11-95H11; Putative malate dehydrogenase 1B
Chromosomal Location2q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MDH1B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMDH1B
Namemalate dehydrogenase 1B, NAD (soluble)
Aliases FLJ25341; RP11-95H11; Putative malate dehydrogenase 1B
Chromosomal Location2q33.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MDH1B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.